


# Petri Bio




*Tomorrow's drugs from  
your inner bugs*


# 90% of all disease states are influenced by gut microbes, including:

- Inflammatory Bowel Disease
- Fatty Liver Disease
- Diabetes
- Heart Disease
- Alzheimer's Disease
- Parkinson's Disease
- Autism
- Epilepsy

Microbes that protect against these disease states are revealed by gene sequencing



But ~99% of microbes fail to grow in the lab for further study and development




???


Problem: millions of beneficial bacteria with potential to cure disease are left unstudied

At Petri Bio, we express these bacteria's genes cell-free, to get the first look at how they can be made into cures

We analyze the genetic sequence of these bacteria to predict and synthesize the most promising compounds




We test these compounds in tissue culture for therapeutic potential






Useful compounds can be marketed as biologic therapeutics,  
or expressed in FDA-approved, food grade probiotics

Encapsulated Peptide  
(therapeutic)



Engineered Probiotic  
(supplement/food)



# Advantages

- Using microbial-peptides as a drug library gives access to millions of new compounds not currently accessed by pharma
- Focusing on unculturable bacteria creates a competitive advantage comparing to other microbiome companies
- Cell-free expression approach enables high-throughput screening faster and cheaper




# Pipeline and milestones

Indication

Product Maturity

Market Size

Viral Infection




**\$2.5 B**  
USD / year

Non-Alcoholic Steatohepatitis (NASH)



**>\$7 B**  
USD / year  
By 2026

Inflammatory Bowel Disease (IBD)



**\$15.9 B**  
USD / year

# Our business model



---

Develop therapeutic candidates targeting three different markets



---

Strategic partnerships w/ pharma companies for drug development; generate early revenue from licensing fee & royalties



---

Clinical trials tested and FDA approved prescription medicine

# Goal and milestones

- We are raising 400k for the next 9 months
- Deliverables:
  - Keep developing current candidates for lab-based proof-of-concepts;
  - File patents to protect the technology;
  - Build out the platform to search for therapies for more diseases

# Our Founders



**Shu Li, Ph.D.**  
*Co-Founder & CEO*

Genetic Engineer  
8 papers, 3 patents  
YC S17

shu@petribio.com



**Joe Schinaman, Ph.D.**  
*Co-Founder & CSO*

Microbiome Scientist  
6 papers, 1 patent  
LA Biostart alumni

joe@petribio.com